Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Teva is the world's largest generic pharmaceutical manufacturer with a portfolio spanning ~3,600 products across CNS, respiratory, oncology, and pain management. The company operates in ~60 countries with major manufacturing facilities in Israel, Europe, and the US, generating approximately 50% of revenue from North America. Teva's competitive position rests on its scale in generics, specialty products like Austedo (tardive dyskinesia) and Ajovy (migraine), and a biosimilars pipeline targeting high-value biologics.
Teva generates profits through vertical integration (API production to finished dosage), manufacturing scale economies enabling 40-50% gross margins on generics, and specialty products commanding premium pricing. The company leverages its global distribution network and regulatory expertise to launch first-to-file generics capturing 180-day exclusivity periods. Pricing power is limited in generics due to commoditization, but specialty products like Austedo (growing 25%+ annually) provide margin expansion. The business model depends on continuous new product launches (30-40 annually) to offset generic erosion and patent cliffs.
Generic drug pricing trends in US market - channel inventory destocking, competitive intensity on key molecules like EpiPen generics
Austedo revenue trajectory and market share gains in tardive dyskinesia/Huntington's chorea indications (currently ~$1.5B run-rate)
Debt reduction progress - company targeting net debt below $15B from current ~$18B, with $1.5B+ annual deleveraging
Pipeline milestones for biosimilars (Humira, Stelara) and complex generics, particularly inhalation and injectable products
Legal settlements and opioid litigation exposure - company reserved $4.5B+ for settlements but faces ongoing state actions
Generic pricing erosion from increased competition and regulatory pressure - US generic prices declined 5-8% annually 2018-2023, though stabilizing recently
Regulatory and political risk around drug pricing reform, including potential Medicare negotiation expansion and state-level price controls
Patent cliff exposure on remaining branded products and biosimilar competition to specialty portfolio (Copaxone already genericized)
Ongoing opioid litigation with potential for additional settlements beyond $4.5B reserved, including criminal liability exposure
Intense generic competition from Indian manufacturers (Sun Pharma, Dr. Reddy's) and other global players with lower cost structures
Specialty product competition - Austedo faces Ingrezza (Neurocrine) in tardive dyskinesia with 60%+ market share; new entrants threaten pricing
Biosimilar market development slower than expected with limited payer adoption and originator rebating strategies maintaining share
Loss of key distribution partnerships or formulary exclusions as PBMs consolidate and demand deeper rebates
Elevated leverage at 3.0x net debt/EBITDA with $18B total debt creates refinancing risk and limits strategic flexibility
Pension and post-retirement obligations exceeding $1B with underfunded status sensitive to discount rate assumptions
Working capital intensity from inventory requirements (6+ months for complex generics) and receivables collection in international markets
Contingent liabilities from legal settlements, environmental remediation at manufacturing sites, and tax disputes in multiple jurisdictions
low - Pharmaceutical demand is non-discretionary and relatively GDP-insensitive. Generic utilization may increase modestly during recessions as patients and payers seek lower-cost alternatives to branded drugs. However, unemployment affecting insurance coverage and Medicaid enrollment shifts can impact payor mix and reimbursement rates. Teva's international exposure (50% ex-US) provides diversification but introduces emerging market currency volatility.
Rising rates increase financing costs on Teva's $18B debt load (weighted average interest rate ~4.5%), with ~40% floating rate exposure creating $70M+ annual cash flow impact per 100bps rate move. Higher rates also pressure valuation multiples for leveraged healthcare companies. However, Teva benefits from USD strength against shekel and European currencies when rates rise, as ~30% of costs are non-USD denominated. The company's debt refinancing schedule shows $2-3B maturities through 2028, making near-term rate environment critical for interest expense trajectory.
Moderate - Teva's BB+ credit rating (one notch below investment grade) affects borrowing costs and access to commercial paper markets. Credit spread widening increases refinancing risk and covenant pressure. The company's ability to maintain $1.5B+ annual free cash flow is critical for debt service ($800M+ annual interest) and avoiding rating downgrades. Tighter credit conditions could force asset sales or equity dilution to meet deleveraging targets.
value - Teva attracts deep value investors focused on turnaround potential, debt reduction, and multiple expansion from trough levels. The 186% net income growth reflects recovery from 2020-2022 restructuring losses rather than sustainable expansion. Current 2.3x P/S and 17.1x EV/EBITDA multiples remain below pre-2017 levels (25-30x) when company carried investment-grade rating. Investors are betting on stabilization of generic pricing, Austedo growth offsetting Copaxone decline, and deleveraging driving re-rating. Limited dividend (suspended 2017) and high debt reduce income investor appeal.
high - Stock exhibits elevated volatility (estimated beta 1.3-1.5) driven by binary events including legal settlements, FDA approvals, and quarterly earnings surprises. The 102.9% one-year return and 86.1% six-month return reflect sentiment shift from distressed levels rather than fundamental stability. Generic pricing volatility, litigation headlines, and refinancing concerns create 20-30% intra-quarter swings. Options market implies 35-40% annualized volatility versus 18-22% for large-cap pharma peers.